Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986288 alone and with nivolumab in advanced solid tumors
NCT03994601Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2019
- Primary completion
- Aug 2024
- Modality
- Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, open-label trial of BMS-986288 in cancer (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety Related Events at 6 months, Dose Limiting Toxicities at 5 weeks and 1 more. Started Sep 2019; status: completed.
02
Drugs
BMS-986288
03
Conditions
cancer
Beyond the preview
Go deeper on NCT03994601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03994601.